Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients

Gisella Guerrera; Alessandra Mandelli; Annamaria Finardi; Mario Orrico; Silvia D’Orso; Mario Picozza; Maddalena Noviello; Valeria Beretta; Bruno Bonetti; Massimiliano Calabrese; Damiano Marastoni; Nicola De Rossi; Ruggero Capra; Marco Salvetti; Maria Chiara Buscarinu; Matilde Inglese; Antonio Uccelli; Lucia Moiola; Catarina Raposo; Erwan Muros‐Le Rouzic; Rosetta Pedotti; Massimo Filippi; Chiara Bonini; Luca Battistini; Giovanna Borsellino; Roberto Furlan

doi:10.1177/13524585221102158

Related publications

Article2021

The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients

Riccardo Levi, Leonardo Ubaldi, Chiara Pozzi, Giovanni Angelotti, Maria Teresa Sandri, Elena Azzolini, Michela Salvatici, Victor Savevski, Alberto Mantovani, María Rescigno

Article2022

SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies

Evangelos Terpos, Despina Fotiou, Vangelis Karalis, Ioannis Ntanasis‐Stathopoulos, Aimilia D. Sklirou, Maria Gavriatopoulou, Panagiotis Malandrakis, Vassiliki A. Iconomidou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A Dimopoulos

Article2022

Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients

Roberta Rovito, Valeria Bono, Matteo Augello, Camilla Tincati, Federica Mainoldi, Guillaume Beaudoin-Bussières, Alexandra Tauzin, Silvia Bianchi, Mohamad Hadla, Vaibhav Yellenki, Antonella d’Arminio Monforte, Stefano Casola, Elisa Borghi, Andrés Finzi, Giulia Marchetti

Article2021

Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis

Diego Curtò, Federica Tomatis, Sara Gastoldi, Miriam Galbusera, Marina Noris, Federico Raimondi, Ferdinando Luca Lorini, Anna Falanga, Marina Marchetti, Giuseppe Remuzzi, Piero Ruggenenti

Preprint2021

Major complex trait for early de novo programming ‘CoV-MAC-TED’ detected in human nasal epithelial cells infected by two SARS-CoV-2 variants is promising for designing therapeutic strategies

José Hélio Costa, Shahid Aziz, Carlos Noceda, Birgit Arnholdt-schmitt

bioRxiv (Cold Spring Harbor Laboratory)